Collaborating for Global Cancer Innovation
BIOHK is an international biotechnology convention that brings together researchers, clinicians, entrepreneurs, industry leaders and investors to exchange knowledge, build partnerships and advance biomedical innovation.
The Asian Fund for Cancer Research Limited (AFCR), through its partnerships with the Hong Kong Biotechnology Organization (HKBIO) and the City University of Hong Kong (CityU), aims to advance cancer breakthroughs that can save patients’ lives and unlock Hong Kong's potential as a leading biomedical innovation hub.
Convene Scientific Exchange
Advance Translational Cancer Research
Discussions explore how advances in genomics, biomarkers, artificial intelligence, earlier detection and emerging treatments can move from research toward clinical application.
Connect Research and Entrepreneurship
Scientists, biotechnology companies, entrepreneurs and investors connect around pathways that can advance promising innovations and support future patient benefit.
Convene Scientific Exchange
Researchers, clinicians and scientific leaders share perspectives on cancer research, precision medicine and emerging biomedical technologies.
Advance Translational Cancer Research
Discussions explore how advances in genomics, biomarkers, artificial intelligence, earlier detection and emerging treatments can move from research toward clinical application.
Connect Research and Entrepreneurship
Scientists, biotechnology companies, entrepreneurs and investors connect around pathways that can advance promising innovations and support future patient benefit.
Looking Ahead to BIOHK2026
9–12 September 2026
We look forward to continuing our engagement at BIOHK2026 and supporting conversations
that connect cancer research, biomedical innovation and entrepreneurship.
Explore More from AFCR at BIOHK
The Asian Fund for Cancer Research Limited supports innovative research and global collaboration designed to accelerate progress against cancer. Your support helps promising discoveries move closer to patients.
